Table 2 In vitro and in vivo studies of nucleotide based STAT inhibitors
Nucleotide based Agent (Ref) | Cancer type studied in vitro(cell lines) | Cancer type studied in vivo(cell lines) | Clinical trial |
|---|---|---|---|
STAT3 ODN (59, 60, 61, 62, 63) | Head & Neck Squamous cell carcinoma (1483), Lung cancer (A549), Colon cancer (SW480), Glioma (U251, A172) | Lung (A549) | Â |
Anti-Sense (AZD9150) (70, NCT01839604) | Â | Â | Non-Hodgkin lymphoma,Hepatocellular carcinoma |
STAT3-siRNA (72, 73, 74, 75, 76, 77, 79) | Breast (MCF7, MDA-MB-231); CML (K562); Glioblastoma (A 172, U251-GM) ; Oral SCC (HSC3, HSC4, KB, GFP-SAS), Epidermoid carcinoma ( STAT3siRNA coupled with mAb to Lewis-Y antigen (A431); CTCL (Hut78) | Breast (MCF7, MDA-MB-231) | Â |
STAT3-G-Quartet (82, 83, 84) | Prostate (PC-3, DU145, LNCap), Breast (MDA-MB-468) | Prostate (PC-3, DU145), Breast (MDA-MB-468) | Â |
STAT5-ODN (64) | Chronic Myeloid Leukemia (K562) | Â | Â |
STAT5- siRNA (72, 81) | CML (K562), Hepatocellular (SMMC7721), | Hepatocellular (SMMC7721), Pancreatic cancer (HPAF-11) | Â |